CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The new online Learning Center with new content can still be found under the “Training” folder on ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...